Vergoeding 2019-2023 voor ATC-subgroep C09CA : Angiotensine-ii-antagonisten
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| C09CA01 Losartan (Cozaar ®) | 5.519.600 | 5.657.900 | 4.900.000 | 5.530.900 | 5.861.500 |
| C09CA02 Eprosartan (Teveten ®) | 113.450 | 48.304 | 52.318 | 51.962 | 51.918 |
| C09CA03 Valsartan (Diovan ®) | 2.708.800 | 2.552.400 | 2.974.500 | 3.445.400 | 3.240.200 |
| C09CA04 Irbesartan (Aprovel ®) | 4.293.900 | 4.164.500 | 3.741.100 | 3.592.300 | 3.380.500 |
| C09CA06 Candesartan (Atacand ®) | 1.778.500 | 2.005.100 | 2.004.100 | 2.122.800 | 1.997.500 |
| C09CA07 Telmisartan (Micardis ®) | 1.285.900 | 1.437.500 | 1.223.700 | 1.288.800 | 1.481.500 |
| C09CA08 Olmesartan (Olmetec ®) | 584.950 | 824.040 | 648.970 | 636.940 | 694.710 |
| Totaal | 16.285.100 | 16.689.744 | 15.544.688 | 16.669.102 | 16.707.828 |